Growth stocks took off during 2020 amid the early stages of the pandemic. Buying during that time led to significant profits for some investors. One of the stocks that benefited from that bullishness ...

As in 2020, CRISPR still doesn't have an approved product -- but that could change soon. The stock has been volatile, providing investors with potential for both big gains and losses. But now that the ...

LabRoots invites you to the 3rd Annual Event in the CRISPR Virtual Event Series! This event will continue the conversation of the abilities of CRISPR-based editing, next-gen editing tools, precision ...

Last year, Verve Therapeutics started the first human trial of a CRISPR treatment that could benefit most people—a signal that gene editing may be ready to go mainstream. CRISPR for high cholesterol ...

Scientists introduced CRISPR to the world as a gene-editing tool in summer 2012, when landmark papers from two independent groups demonstrated how the system could be wielded to make cuts in DNA. Now, ...

CRISPR has taken the bioengineering world by storm since its first introduction. From treating sickle cell diseases to creating disease-resistant crops, the technology continues to boast success on ...

Genome editing technologies, such as CRISPR, are being applied to better understand basic biological systems as well as to research new kinds of gene and cell therapies. The CRISPR-Cas9 system ...

Rare genetic diseases are challenging for patients and their families—made all the more overwhelming because symptoms tend to appear soon after birth. To date, there haven’t been many reliable ...